Immuneering Corp
NASDAQ:IMRX
Immuneering Corp
Accounts Payable
Immuneering Corp
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Immuneering Corp
NASDAQ:IMRX
|
Accounts Payable
$2.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is Immuneering Corp's Accounts Payable?
Accounts Payable
2.1m
USD
Based on the financial report for Dec 31, 2023, Immuneering Corp's Accounts Payable amounts to 2.1m USD.
What is Immuneering Corp's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
12%
Over the last year, the Accounts Payable growth was -34%. The average annual Accounts Payable growth rates for Immuneering Corp have been 12% over the past three years .